Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novo Nordisk has launched Saxenda (liraglutide [rDNA origin] injection), the first glucagon-like peptide-1 (GLP-1) receptor agonist for weight management in adults, in the US.
Subscribe to our email newsletter
In the US, Saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity or who are overweight in the presence of at least one weight-related comorbid condition.
The drug was evaluated in the SCALE Phase III clinical program, which involved more than 5,000 study participants.
Data from the trial showed that Saxenda, in combination with a reduced-calorie diet and increased physical activity, resulted in weight loss than reduced-calorie diet and physical activity alone.
Novo Nordisk Marketing, Medical Affairs & Stakeholder Engagement executive vice-president Jakob Riis said: "We are pleased to make this new treatment option available, which we believe has the potential to help people with obesity lose weight and reduce weight-related comorbidities.
"The launch of Saxenda is an important milestone in Novo Nordisk’s long-term commitment to obesity treatment and we look forward to launching Saxenda in other countries later in 2015."
Currently, Saxenda is approved in the US, European Union (EU) and Canada, and the company intends to launch the drug in several other markets later in 2015.
Image: Novo Nordisk’s Saxenda is indicated for weight management for adults in the US. Photo: courtesy of Baitong333/ freedigitalphotos.net.